Novel Approaches to Increase Morbillivirus Yield from Eukaryotic Cells In Vitro

A global Fortune 500 company is seeking novel approaches to increase the viral yield from eukaryotic cell cultures in vitro, with particular interest in increasing the yield of Morbilliviruses in established cell lines. Specifically, they are interested in methods to increase the titer of virus propagation during in vitro infection, increasing virus secretion or release into cell culture media from infected cells, and/or scalable approaches to concentrate live viral fluids.

Approaches of Interest:

- Novel methods to directly improve the yield of Morbillivirus from any eukaryotic cells in vitro, with a focus on cell lines or cells which have potential to be immortalised
- Cell culture media or supplements to increase/enhance viral yield
- Novel approaches to improving yield of related viruses from eukaryotic cells in vitro, which can be applied to Morbillivirus

Out of Scope:

- Methods of increasing viral yield which cannot be applied to morbillivirus
- Propagation in non-eukaryotic cells

Developmental Stages of Interest:

- Research with in vitro validation or proof of concept are preferred (i.e. data that demonstrate a minimum of 10-fold increase in live virus titer). Early stage research with clear application to the field are also of interest
- Our client is interested in engaging with researchers with expertise in viral propagation that can be applied to improving the yield of morbillivirus from eukaryotic cells in vitro

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to receiving proposals for novel research projects using this application form. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and ongoing research collaboration, funding support for promising research.